[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340543-105":59,"doc-detail-340543-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","associations-of-the-expression-levels-and-risk-variants-of-cdkn2b-as1-long-noncoding-rna-with-the-susceptibility-and-progression-of-prostate-cancer-original-article","Associations of the Expression Levels and Risk Variants of CDKN2B-AS1 Long Noncoding RNA With the Susceptibility and Progression of Prostate Cancer - Original Article","","Genetic variants of deregulated long noncoding RNAs contribute to tumorigenesis, progression, and recurrence, yet the role of CDKN2B-AS1 in prostate cancer remains insufficiently clarified. This case–control study assessed CDKN2B-AS1 expression levels and variants in 695 prostate cancer patients and 695 healthy controls. The rs1333048 minor C allele increased tumor risk and associated high Gleason grades, especially without biochemical recurrence. Bioinformatic and cellular analyses supported higher CDKN2B-AS1 expression with the C allele and links to aggressive clinical features, suggesting a mechanism accelerating progression.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/associations-of-the-expression-levels-and-risk-variants-of-cdkn2b-as1-long-noncoding-rna-with-the-susceptibility-and-progression-of-prostate-cancer-original-article/340543/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/associations-of-the-expression-levels-and-risk-variants-of-cdkn2b-as1-long-noncoding-rna-with-the-susceptibility-and-progression-of-prostate-cancer-original-article/340543.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the main purpose of the study?","Question",{"text":113,"@type":114},"To evaluate whether CDKN2B-AS1 expression levels and genetic risk variants are associated with prostate cancer susceptibility and progression.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which genetic variant showed an increased risk association in prostate cancer patients?",{"text":118,"@type":114},"Under a dominant model, carriers of at least one minor C allele of rs1333048 had an increased risk of developing tumors with high Gleason grades.",{"name":120,"@type":111,"acceptedAnswer":121},"How did higher CDKN2B-AS1 expression relate to clinical outcomes?",{"text":122,"@type":114},"Higher CDKN2B-AS1 levels correlated with larger tumor sizes, lymph node metastasis, higher Gleason scores, and shorter progression-free survival.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},340543,1790176918,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","Journal of Cellular and Molecular Medicine  \nORIGINAL ARTICLE  OPEN ACCESS   \nAssociations ofthe Expression Levels and Risk Variants of CDKN2B-AS1 Long Noncoding RNA With the Susceptibility and Progression of Prostate Cancer  \nMin-Che Tung1,2 | Chia-Yen Lin3,4,5 | Yu-Ching Wen6,7 | Lun-Ching Chang8 | Shun-Fa Yang9,10  | Ming-Hsien Chien2,11,12,13   \n1Division of Urology, Department of Surgery, Tungs' Taichung Metro Harbor Hospital, Taichung, Taiwan | 2Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan | 3Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan | 4School of Medicine, Chung Shan Medical University, Taichung, Taiwan | 5School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan | 6Department of Urology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan | 7Department of Urology, School of Medicine, College of Medicine and TMU Research Center of Urology and Kidney (TMU-RCUK), Taipei Medical University, Taipei, Taiwan | 8Department of Mathematical Sciences, Florida Atlantic University, Florida, USA | 9Institute of Medicine, Chung Shan Medical University,  \nTaichung, Taiwan | 10Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan | 11Pulmonary Research Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan | 12Traditional Herbal Medicine Research Center, Taipei Medical University Hospital, Taipei,  \nTaiwan | 13TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan Correspondence: Shun-Fa Yang ([ysf@csmu.edu.tw](ysf@csmu.edu.tw)) | Ming-Hsien Chien ([mhchien1976@gmail.com](mhchien1976@gmail.com))  \nReceived: 29 October 2024 | Revised: 20 November 2024 | Accepted: 23 November 2024  \nFunding: This work was supported by Wan Fang Hospital, 113-wf-swf-05.  \nKeywords: cancer progression | cancer susceptibility | cyclin-dependent kinase inhibitor 2B antisense RNA 1 | long noncoding RNA | prostate cancer | single-nucleotide polymorphism  \nABSTRACT  \nGenetic variants of deregulated long noncoding RNAs (lncRNAs) have been implicated in tumorigenesis, cancer progression and cancer recurrence. Single-nucleotide polymorphisms (SNPs) of the lncRNA cyclin-dependent kinase inhibitor 2B antisense RNA 1 (CDKN2B-AS1) have been associated with the risk and progression of various cancers; however, their role in prostate cancer (PCa) remains underexplored. In this case–control study, we investigated the associations of CDKN2B-AS1 expression levels and variants with PCa risk and progression. For this, five SNPs of CDKN2B-AS1—rs564398, rs1333048, rs1537373, rs2151280 andrs8181047—were genotyped using a TaqMan allelic discrimination assay; data were collected from 695 patients with PCa and 695 healthy controls. Our findings revealed that, under a dominant model, patients with PCa carrying at least one minor C allele of rs1333048 exhibited an increased risk of developing tumours with high Gleason grades; this risk was particularly high in patients without biochemical recurrence. Data from the Genotype-Tissue Expression database indicated upregulated CDKN2B-AS1 expression in the prostates of individuals carrying the polymorphic C allele of rs1333048 . Genotype screening of rs1333048 in PCa cell lines showed that cells with at least one minor C allele had higher CDKN2B-AS1 levels than those with the AA genotype. Furthermore, data from The Cancer Genome Atlas indicated that higher CDKN2B-AS1 levels in PCa tissues were correlated with larger tumour sizes (T3 + T4), more lymph node metastasis (N1), higher Gleason scores and shorter progression-free survival. In conclusion, the polymorphic variants of CDKN2B-AS1 at rs1333048 may modulate CDKN2B-AS1 expression, thus accelerating PCa progression.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any","cbCaiqproBo27baS","https://ap.wps.com/l/cbCaiqproBo27baS","pdf",1026486,13,"English","# Abstract\n# Introduction","[{\"question\":\"What was the main purpose of the study?\",\"answer\":\"To evaluate whether CDKN2B-AS1 expression levels and genetic risk variants are associated with prostate cancer susceptibility and progression.\"},{\"question\":\"Which genetic variant showed an increased risk association in prostate cancer patients?\",\"answer\":\"Under a dominant model, carriers of at least one minor C allele of rs1333048 had an increased risk of developing tumors with high Gleason grades.\"},{\"question\":\"How did higher CDKN2B-AS1 expression relate to clinical outcomes?\",\"answer\":\"Higher CDKN2B-AS1 levels correlated with larger tumor sizes, lymph node metastasis, higher Gleason scores, and shorter progression-free survival.\"}]","Associations of the Expression Levels and Risk Variants of CDKN2B-AS1 Long Noncoding RNA With the Susceptibility and Progression of Prostate Cancer - Original Article | PDF",1790037256,33]